Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.34 Increased by +143.04% | 0.05 Increased by +580.00% |
| Feb 27, 24 | -0.50 Increased by +34.21% | -0.48 Decreased by -4.17% |
| Nov 7, 23 | -0.37 Increased by +54.32% | -0.43 Increased by +13.95% |
| Aug 1, 23 | -0.46 Increased by +56.19% | -0.61 Increased by +24.59% |
| May 9, 23 | -0.79 Increased by +15.05% | -0.65 Decreased by -21.54% |
| Feb 21, 23 | -0.76 Increased by +57.06% | -0.84 Increased by +9.52% |
| Nov 1, 22 | -0.81 Increased by +69.08% | -0.92 Increased by +11.96% |
| Aug 2, 22 | -1.05 Increased by +37.13% | -0.93 Decreased by -12.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 33.97 M Increased by +78.97% | -41.25 M Increased by +39.88% | Decreased by -121.43% Increased by +66.41% |
| Jun 30, 23 | 25.79 M Increased by +36.86% | -49.94 M Increased by +37.79% | Decreased by -193.65% Increased by +54.55% |
| Mar 31, 23 | 24.33 M Increased by +29.16% | -89.22 M Decreased by -26.60% | Decreased by -366.72% Increased by +1.98% |
| Dec 31, 22 | 18.82 M Increased by +22.19% | -68.46 M Decreased by -5.13% | Decreased by -363.81% Increased by +13.96% |
| Sep 30, 22 | 18.98 M Increased by +31.72% | -68.61 M Increased by +1.12% | Decreased by -361.49% Increased by +24.93% |
| Jun 30, 22 | 18.84 M Decreased by -53.66% | -80.27 M Decreased by -83.82% | Decreased by -426.05% Decreased by -296.69% |
| Mar 31, 22 | 18.84 M Increased by +136.10% | -70.47 M Increased by +22.50% | Decreased by -374.14% Increased by +67.18% |
| Dec 31, 21 | 15.40 M Increased by +59.79% | -65.12 M Increased by +37.67% | Decreased by -422.82% Increased by +60.99% |